GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Beta

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Beta : 0.27 (As of May. 01, 2024)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-01), Alseres Pharmaceuticals's Beta is 0.27.


Alseres Pharmaceuticals Beta Historical Data

The historical data trend for Alseres Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Beta Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.32 0.15 0.46 0.11

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.02 0.11 -0.08 -0.28

Competitive Comparison of Alseres Pharmaceuticals's Beta

For the Biotechnology subindustry, Alseres Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Beta falls into.



Alseres Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Alseres Pharmaceuticals  (OTCPK:ALSE) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Alseres Pharmaceuticals Beta Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines